Sanofi SA

Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients

13 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants

08 Jun 2023 17:19:00 By Nasdaq GlobeNewswire

Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan  

01 Jun 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

31 May 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

25 May 2023 12:10:28 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

21 May 2023 14:17:08 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – April 2023

17 May 2023 16:01:19 By Nasdaq GlobeNewswire

Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

12 May 2023 04:50:00 By Nasdaq GlobeNewswire

Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS

04 May 2023 02:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

27 Apr 2023 08:40:15 By Nasdaq GlobeNewswire

Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

27 Apr 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

26 Apr 2023 02:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2023

19 Apr 2023 15:05:19 By Nasdaq GlobeNewswire

Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

11 Apr 2023 02:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

10 Apr 2023 16:15:00 By Nasdaq GlobeNewswire

Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

04 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

30 Mar 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

23 Mar 2023 02:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

21 Mar 2023 02:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

18 Mar 2023 10:00:00 By Nasdaq GlobeNewswire